CN102258751A - 用于治疗忧郁症、消愁解忧、善解抑郁的中药薄荷 - Google Patents
用于治疗忧郁症、消愁解忧、善解抑郁的中药薄荷 Download PDFInfo
- Publication number
- CN102258751A CN102258751A CN2011102052844A CN201110205284A CN102258751A CN 102258751 A CN102258751 A CN 102258751A CN 2011102052844 A CN2011102052844 A CN 2011102052844A CN 201110205284 A CN201110205284 A CN 201110205284A CN 102258751 A CN102258751 A CN 102258751A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- mint
- medicine composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 208000020401 Depressive disease Diseases 0.000 title claims abstract description 15
- 208000024714 major depressive disease Diseases 0.000 title claims abstract description 15
- 201000003995 melancholia Diseases 0.000 title claims abstract description 15
- 235000002899 Mentha suaveolens Nutrition 0.000 title abstract description 10
- 235000006679 Mentha X verticillata Nutrition 0.000 title abstract description 8
- 235000001636 Mentha x rotundifolia Nutrition 0.000 title abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 13
- 230000000994 depressogenic effect Effects 0.000 claims description 12
- 239000006187 pill Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 235000015511 Liquidambar orientalis Nutrition 0.000 claims description 4
- 239000004870 Styrax Substances 0.000 claims description 4
- 244000028419 Styrax benzoin Species 0.000 claims description 4
- 235000000126 Styrax benzoin Nutrition 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000010271 massa medicata fermentata Substances 0.000 claims description 4
- 235000014375 Curcuma Nutrition 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 2
- 244000164439 Curcuma angustifolia Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 230000006870 function Effects 0.000 abstract description 12
- 208000024891 symptom Diseases 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000007958 sleep Effects 0.000 abstract description 3
- 230000006399 behavior Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 235000017924 poor diet Nutrition 0.000 abstract 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 30
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 26
- 229940041616 menthol Drugs 0.000 description 26
- 239000000341 volatile oil Substances 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 239000000284 extract Substances 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 229930007503 menthone Natural products 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 206010037844 rash Diseases 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000010201 Exanthema Diseases 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 230000001139 anti-pruritic effect Effects 0.000 description 4
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 210000003026 hypopharynx Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000001256 steam distillation Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 2
- NFLGAXVYCFJBMK-IUCAKERBSA-N (-)-isomenthone Chemical compound CC(C)[C@@H]1CC[C@H](C)CC1=O NFLGAXVYCFJBMK-IUCAKERBSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 244000182807 Mentha suaveolens Species 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241001643642 Viticis Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229930006739 camphene Natural products 0.000 description 2
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 2
- 230000035568 catharsis Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000007803 cold maceration Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 2
- 229960000385 dyclonine Drugs 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- HKZQJZIFODOLFR-UHFFFAOYSA-N piperitenone Chemical compound CC(C)=C1CCC(C)=CC1=O HKZQJZIFODOLFR-UHFFFAOYSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 2
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000002047 solid lipid nanoparticle Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 239000008539 xiaoyao Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000255791 Bombyx Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241001604074 Lippia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- VFFCBWDFYBEZAX-YCRREMRBSA-N Menthoside Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C=C(O3)C=3C=CC(OC(=O)\C=C\C=4C=C(O)C(O)=CC=4)=CC=3)=O)=C(O)C=2)O1 VFFCBWDFYBEZAX-YCRREMRBSA-N 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 235000010688 Yerba dulce Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000010218 duhuo jisheng Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HEILIGJNYTWOHU-UHFFFAOYSA-N ethanol 2-hydroxybenzoic acid Chemical compound CCO.OC(=O)C1=CC=CC=C1O HEILIGJNYTWOHU-UHFFFAOYSA-N 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 229940076988 freshmint Drugs 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- -1 glucosides flavone compound Chemical class 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008361 herbal raw material Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- SEZLYIWMVRUIKT-UHFFFAOYSA-N isopiperitenone Natural products CC(=C)C1CCC(C)=CC1=O SEZLYIWMVRUIKT-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000002272 menthone group Chemical group 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003895 organic fertilizer Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000010181 polygamy Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了用于治疗忧郁症、消愁解忧、善解抑郁的中药薄荷,或者含有薄荷为原料的药物组合物,或者由薄荷为原料的提取物做活性成分在制造药物中的应用,该药物用于治疗忧郁症、消愁解忧、善解忧郁功效的中药。本发明还公开了制备具有上述预防和治疗用途的药物制备方法。本发明为薄荷原有公开药效外新的药物用途。本发明可显著改善:情绪低落,兴趣减低,悲观,思维迟缓,缺乏主动性,自责自罪,饮食、睡眠差,担心自己患有各种疾病,感到全身多处不适,严重者可出现自杀念头和行为。临床疗效确切,疗效显著,见效迅速。本发明中药组合物还具有安全、费用低廉、远期疗效更稳定可靠的优点。
Description
技术领域
本发明涉及用于治疗忧郁症、消愁解忧、善解抑郁功效的中药薄荷。尤其涉及以中草药薄荷为原料药的用于治疗忧郁症、消愁解忧、善解抑郁功效的中药及其制备方法。
背景技术
忧郁症是情感性疾病,是一种以深重的忧郁为特征的疾病。主要表现为情绪低落,兴趣减低,悲观,思维迟缓,缺乏主动性,自责自罪,饮食、睡眠差,担心自己患有各种疾病,感到全身多处不适,严重者可出现自杀念头和行为。忧郁症发病率很高,几乎每7个成年人中就有1个抑郁症患者,因此它被称为精神病学中的感冒。忧郁症目前已成为全球疾病中给人类造成严重负担的第二位重要疾病,对患者及其家属造成的痛苦,对社会造成的损失是其他疾病所无法比拟的。
现代医学针对临床某一症状治疗,往往达不到预期效果,找不到合适的治疗方法,为了克服上述缺陷,本发明基于中医治疗忧郁的辨病与辨证相结合的原则,标本兼治,虚实并治,内外通调,缓急兼收,在总结临床经验的基础上,筛选出天然植物药薄荷、薄荷中药提取物,并对其作用机制进行了深入研究。提供一种疗效显著、成本低廉、毒副作用极小的善解忧郁的中药。
相关领域最新研究成果
一、中药薄荷的功能主治及现代研究
(一)薄荷的功能主治
薄荷属性辛凉,为唇形科植物,在中国大部分地方都有出产,主要于江苏、浙江、江西等地。薄荷具有特殊的芳香、辛辣感和凉感。在医药上广泛用于驱风、防腐、消炎、镇痛、止痒、健胃等药品中。全草入药,辛,凉。归肺、肝经。有发散风热,清利咽喉,透疹解毒,疏肝解郁和止痒等功效,适用于感冒发热、头痛、咽喉肿痛、无汗、风火赤眼、风疹、皮肤发痒、疝痛、下痢及瘰疬等症,外用有轻微的止痛作用,用于神经痛等。
1、用于风热感冒,温病初起。本品辛以发散,凉以清热,清轻凉散,为疏散风热常用之品,故可用治风热感冒或温病初起,邪在卫分,头痛、发热、微恶风寒者,常配银花、连翘、牛蒡子、荆芥等同用,如银翘散。
2、用于头痛目赤,咽喉肿痛。本品轻扬升浮、芳香通窍,功善疏散上焦风热,清头目、利咽喉。用治风热上攻,头痛目赤,多配合桑叶、菊花、蔓荆子等同用;用治风热壅盛,咽喉肿痛,常配桔梗、生甘草、僵蚕、荆芥、防风等同用。
3、用于麻疹不透,风疹瘙痒。本品质轻宣散,有疏散风热,宣毒透疹之功,用治风热束表,麻疹不透,常配蝉蜕、荆芥、牛蒡子、紫草等,如透疹汤;治疗风疹瘙痒,可与苦参、白鲜皮、防风等同用,取其祛风透疹止痒之效。
4、用于肝郁气滞,胸闷胁痛。本品兼入肝经,能疏肝解郁,常配合柴胡、白芍、当归等疏肝理气调经之品,治疗肝郁气滞,胸胁胀痛,月经不调,如逍遥散。
5、此外,本品芳香辟秽,还可用治夏令感受暑湿秽浊之气,所致痧胀腹痛吐泻等症,常配藿香、佩兰、白扁豆等同用。
(二)薄荷的现代研究
薄荷的主要成分是挥发油、酚类。新鲜薄荷叶含挥发油0.8%-1%,干茎叶含1.3%-2%。油中主成分为薄荷醇或薄荷脑(Menthol),含量约77%-78%,其次为薄荷酮(Menthone), 含量为8%-12%。还含有乙酸薄荷脂(Menthyl acetate)、莰烯(Camphene)、 柠檬烯(Limonene)、异薄荷酮(Isomenthone)、蒎烯(Pinene)、薄荷烯酮(Menthenone)。酚类成分有异端叶灵(Isoraifolin)、薄荷糖苷(Menthoside)等黄酮类化合物及少量鞣质,迷迭香酸(Rosmarinicacid)和咖啡酸。
药理研究证明,薄荷油内服通过兴奋中枢神经系统,使皮肤毛细血管扩张,促进汗腺分泌,增加散热,而起到发汗解热作用;薄荷油能抑制胃肠平滑肌收缩,能对抗乙酸胆碱而呈现解痉作用;薄荷油能促进呼吸道腺体分泌而对呼吸道炎症有治疗作用;体外试验薄荷煎剂对单纯性疱疹病毒、森林病毒、流行性腮腺炎病毒有抑制作用,对金黄色葡萄球菌、白色葡萄球菌、甲型链球菌、乙型链球菌、卡他球菌、肠炎球菌、福氏痢疾杆菌、炭疽杆菌、白喉杆菌、伤寒杆菌、绿脓杆菌、大肠杆菌等有抑菌作用;薄荷油外用,能刺激神经末梢的冷感受器而产生冷感,并反射性地造成深部组织血管的变化而起到消炎、止痛、止痒作用。
二、薄荷善解忧郁的作用研究
中医认为,正常的精神活动并不会影响人体的脏腑,但是精神刺激,或是心理调节能力较弱,则会影响脏腑的功能活动,从而产生相应的症状。其中肝在情志的调节中起重要的作用,强烈的精神刺激往往会导致肝的疏泄功能受到抑制,不能调畅情志则会产生闷闷不乐,而这正是忧郁症的主要症状。
薄荷气味芳香怡人,不少口气清新产品都取材薄荷。而薄荷的药用价值很高,除了可以发散风热,清利咽喉,透疹止痒外,还有极好的疏肝解郁的功效。和其他气味芳香的花草一样,薄荷能改善抑郁、暴怒等不良情绪,为解郁之良药。
中医理论认为,肝“主疏泄、喜条达而恶抑郁”,而薄荷药性辛、凉,善入肝经,具有疏肝解郁的功效,能够顺应肝的条达之性,发泄其郁遏之气,既能舒肝,又能和脾,而善解郁结,特别适用于肝郁气滞证的患者。代表方剂为逍遥散(柴胡、当归、白芍、白术、茯苓、甘草、生姜、薄荷),对肝郁气滞所致的胸胁乳房胀痛、口燥咽干、月经不调等症有较好疗效。
本发明的上述中药组合物加入制备不同的剂型时所需的各种常规辅料,例如崩解剂、润滑剂、黏合剂等以常规的中药制剂方法制备成任何一种常用的口服制剂,例如可以是:丸剂、胶囊剂、片剂、散剂、颗粒剂或口服液等。
发明内容
本发明所要解决的技术问题是提供一种疗效显著、成本低廉、几乎无毒副作用的用于治疗忧郁症、消愁解忧、善解抑郁功效的中药薄荷及其制备方法。
本发明所要解决的技术问题是通过以下技术途径来实现的。
本发明的用于治疗忧郁症、消愁解忧、善解抑郁功效的中药,主要以下重量份的组分组成:
薄荷(新鲜根、茎、叶)1~1000份、郁金1~20份、木香1~15份、川楝子1~30、乌药1~20、降香1~20份、沉香1~15份、枳实1~30份、青皮1~20份。
优选为:
薄荷(新鲜根、茎、叶)1~50份、郁金15份、木香15份、川楝子15、乌药15、降香15份、沉香10份、枳实15份、青皮10份。
本发明的中药组合物各组分的重量份用量还可以是:
陈皮1~30份、神曲1~30份、酸枣仁1~15份、夜交藤1~15份、乌药1~30份、苏合香1~20份、石菖蒲1~30份、香附子1~30份。
优选为:
陈皮20份、神曲20份、酸枣仁10份、夜交藤10份、乌药15份、苏合香15份、石菖蒲15份、香附子15份。
本发明的上述中药组合物加入制备不同剂型时所需的各种常规辅料,例如崩解剂、润滑剂、黏合剂等以常规的中药制剂方法制备成任何一种常用的口服制剂,例如可以是丸剂、胶囊剂、片剂、散剂、颗粒剂或口服液等。
本发明中药组合物基于中医五脏阴阳辨证纲领的创新思路,结合泰一和浦创新理论体系“万病归宗理论”、“五脏阴阳辨证纲领”、“三维守恒调控法则”和临床治疗“双合原则”作为指导,结合疾病发生、发展及转变的规律,按照创新药物体系进行分类,形成以“五脏基本功能调整、阴阳平衡协调方”为君,“五脏主要病机调整方”为臣,“重大疾病治疗方”为佐,“临床基本症状对症治疗方”为使的中药成药“创新药物体系”。
本发明所用的中草药原料药均可从中医药店购得,其规格符合国家医药标准。
用法用量:本发明的用药量取决于具体剂型,病人年龄、体重、健康状况等因素。作为指导:内服:1)胶囊剂:每天三次,每次服2~5粒,每粒含药量0.4克,温水送服。2)片剂:每天三次,每次2~4片,每片含药量0.5克,温水送服。3)丸剂:每天三次,每次5克,温水送服。4)颗粒剂:每天三次。每次5克,温水送服。
本发明针对忧郁症、抑郁症、焦虑症的预防和治疗非常有效,各种原料药相互协调在一起能够起到最大程度发挥药效,可有效提高患者机体的自我协调能力,显著改善脏腑功能和临床自觉症状,此外还具有无毒副作用、费用较低等优点。
具体实施方式
以下通过实施例来进一步描述本发明,应该理解的是,这些实施例仅用于例证的目的,绝不限于本发明。
薄荷中主要成分为挥发油,挥发油中主要有效成分为薄荷醇(俗称薄荷脑)。如何提高薄荷油出油率和薄荷醇得率是薄荷油提取工艺研究的主要内容之一。薄荷挥发油的提取方法较多,如水蒸气蒸馏法、冷浸法、超声波法、超临界CO2法等,目前国内外主要以水蒸气蒸馏法提取为主。
(一)薄荷挥发油的提取方法
1、水蒸气蒸馏法提取
称取粉碎好的薄荷200g,置挥发油提取器中,加水1000ml,按《中国药典》2000版附录XD挥发油测定法提取挥发油。提取6h,收集薄荷油。用无水硫酸钠脱水,滤纸过滤。
2、冷浸法提取
称取薄荷粉末20g,用600ml石油醚室温浸泡3次,每次用200ml溶剂,浸泡时间为3 h/次,合并提取液,将滤液在旋转蒸发仪上蒸去石油醚。
3、超声波法提取
称取薄荷粉末20g,以200ml石油醚为溶剂,超声提取3次。超声频率40 kHz,提取时间为30min/次。合并提取液,将滤液在旋转蒸发仪上蒸去石油醚。
4、超临界CO2法提取
称取薄荷粉末1.3kg,装入萃取釜。在萃取压力为9 MPa,萃取温度为50℃,CO2流量为25L/h的条件下,萃取1.5h,收集薄荷油。
5、超微粉碎提取法
将薄荷(晒干)及含有薄荷的药物组合物混合,加入到超微粉碎机中,调到1500目至2500目,进行超微粉碎,提取出的超微粉末即得。
超微粉碎的最大益处在于,不丢失薄荷原材料中的任何有效成分,使得薄荷全部有效成分得以保留和应用,这也是中药材在遵循传统加工炮制理念的基础上,与现代化中药制药手段有机结合的典范。
中药超微加工能够最大限度的提取中药材有效成分,可以节约大量中药材资源,超微加工不需要加入任何添加剂,不发生化学变化,既减少了对中药材有效成分可能存在的不利影响,又能使中药材保持最佳的功能、功效,超微加工后的中药材剩余物总量很少,并且可以用作有机肥料,减少对环境的污染。中药材超微加工后使用剂量大大减少,疗效大大提升,中药原料储存、运输、保管、使用都很方便易行。通过对比试验可以证明,中药材经超微加工后,等量疗效可以提升几倍甚至几十倍,而等效用量可以减少几倍甚至几十倍。中药超微技术是一种非常经济合理的加工方式,也必将成为中药材走向世界市场的有力推手。
(二)薄荷挥发油的制剂研究
1 常规方法 即待制剂进入最后阶段时将挥发油喷入和兑入的方法,但此法难以有效遏止挥发油的挥散。杨基森等分别用硅藻土、氢氧化铝、活性炭的粉末及颗粒进行透骨草油吸附率及加速稳定性实验,结果发现:硅藻土及氢氧化铝凝胶粉末吸附透骨草油较颗粒吸附量高;而活性炭颗粒吸附量较粉末高,但粉末较颗粒挥发量低。
2 包合物 林於等利用N-LOK与β-CD对独活寄生颗粒中挥发油进行包合,经分析结果表明:包合前后挥发油主要成分基本一致,但N-LOK对挥发油的包合率约为β-CD的2倍,而且N-LOK挥发油包合物含油率高,可直接喷雾干燥,因此其更接近于中成药工业规模生产实际。
包合技术改变了挥发油的物理性质,增加了中药挥发性成分的稳定性,提高了药物的溶解度,降低了药物的刺激性等,为中药新剂型的开发提供了依据。
3 外用制剂 可据挥发油的药理作用制备成外用制剂,如擦剂、洗剂、软膏等。Oladimeji FA等从过江藤属植物叶中提取的挥发油制成20%的混悬液。姜洪芳等将丹皮酚W/O/W型复乳制成凝胶,具有药物浓度高,不易挥发,作用持久,成膜性好且具缓释作用。
4 软胶囊剂 以明胶甘油为囊材,将挥发油制成软胶囊,使其稳定性及生物利用度皆有较大提高。张振秋等将大蒜油、王浆等制备成复方大蒜油软胶囊。
5 滴丸剂 挥发油制成滴丸后,疗效迅速,生物利用度高,自动化程度高,设备简单等。已有的中药滴丸品种有:芸香滴丸、牡荆油滴丸、薄荷滴丸、苏冰滴丸等。
6 固体脂质纳米粒 韩静等研究了降香挥发油-SLN的制备工艺和影响因素,并用熔融-超声法和高压乳匀法制成稳定的固体脂质纳米粒分散体。将挥发油分散后使粒径达到纳米水平,可提高药物的生物利用度,产生许多新的功效。
7 脂质体 罗琥捷等用酰化磷脂以逆相蒸发-搅拌超声法制备鱼腥草挥发油脂质体,过柱分离检测包封率,并用显微镜法观察形态。通过气质联用和抑菌圈实验比较脂质体与乳剂给药浓度,结果挥发油纳米酰化磷脂脂质体肺靶向效果优于乳剂。脂质体可包裹脂溶性和水溶性药物;脂质体具有靶向性,尚能降低药物毒性,增强药理作用,延长药物作用时间,增加药物的体内外稳定性。
8 其他 挥发油经包合后可直接制成颗粒剂、硬胶囊剂、片剂、栓剂、微囊剂等;也可被制成乳剂、微球剂、气雾剂等其他剂型。
[实验例 ] 本发明中药组合物用于治疗忧郁症、抑郁症、焦虑症患者的临床疗效观察实验
1、对中枢神经系统的作用,改善焦虑、抑郁症状
薄荷醇能加强戊巴比妥钠的中枢抑制作用,且具有一定的量效关系。薄荷醇0.9g/kg灌胃,能明显缩短戊巴比妥钠诱导的小鼠入睡潜伏期[从对照组的(8.31±5.46)min降至(2.62±0.79)min],增加小鼠急性死亡率,但对睡眠时间无明显影响。0.3g/kg、0.1g/kg灌胃也能缩短戊巴比妥钠诱导的小鼠入睡时间,与对照组比较差异无显著性。同属植物圆叶薄荷精油和欧薄荷精油均有中枢抑制作用,50mg/kg腹腔注射能明显延长戊巴比妥钠诱导的小鼠睡眠时间。欧薄荷油对中枢神经系统的抑制作用强于圆叶薄荷油,两者对大鼠的条件反射无明显影响,不同剂量都能降低大鼠和小鼠的体温。
2、清爽、除烦、止痒作用
薄荷油具有清爽、除烦、止痒作用,外用能麻醉神经末梢。薄荷醇和薄荷酮对皮肤均有刺激作用,薄荷醇应用于皮肤,先产生冷感,后有轻微的刺灼感。张氏观察52例乳腺癌根治术后接受放疗的患者,观察组自放疗开始日起在放疗部位搽用复方薄荷脑(薄荷脑2g+淀粉98g),每日上下午照射后各用1次,对照组不用药物。结果观察组患者各放射皮肤放射反应发生率明显降低,但放射反应发生顺序及出现反应时间与对照组相同。
3、疏肝利胆、行气解郁作用
薄荷醇或薄荷酮260μmol/kg(约40mg/kg)给大鼠口服,有较强的疏肝利胆作用,给薄荷醇3h-4h后,胆汁排出量约增加4倍,随后作用减弱;薄荷酮作用相似,但较持久,给药5h后,胆汁排出量增加50%-100%。薄荷的丙酮干浸膏或50%甲醇干浸膏(有效成分为薄荷醇)50mg/kg十二指肠给药,对麻醉大鼠有显著的疏肝利胆作用,给药后0.5h-1h作用达高峰,胆汁排出量约为对照组的2-4倍。
4、其他辅助解忧作用
薄荷醇有镇咳作用。家兔吸收薄荷醇蒸气能使呼吸道粘膜分泌增加,使粘液稀释而表现祛痰作用。薄荷冰片(薄荷油炼制的结晶)可引起鼻气道通畅,增加血氧交换量,从而保持呼吸顺畅,心情舒畅,但对鼻气道阻力无明显影响,可能是其作用于鼻内的三叉神经感觉末梢,使人产生鼻通气快感。薄荷油湿热敷可有效预防术后腹胀,促进肛门排气,同时有减轻疼痛的作用。
5、 其它作用
5.1 抗炎镇痛作用
薄荷提取物(有效成分为薄荷醇)250mg/kg腹腔注射对大鼠角叉菜胶性足肿胀的抑制率为60%-100%;有效成分为薄荷酮的薄荷提取物1mg/kg皮下注射,对小鼠醋酸扭体反应的抑制率为30%-60%。左旋薄荷酮100mg/kg灌胃,对小鼠醋酸扭体反应的抑制率为41.3%。目前亦有报道薄荷醇0.9g/kg、0.3 g/kg 、0.1 g/kg灌胃,对热板致小鼠痛阈无明显影响,但可明显增强柴胡的镇痛作用。
5.2 对平滑肌的作用
在离体状态下,薄荷醇对家兔、豚鼠的回肠、子宫活动的张力、强度、强度-张力差均有明显的抑制作用,并能对抗组胺、乙酰胆碱、氯化钡等引起的肠管活动亢进。以薄荷醇23mg/kg灌胃,对小鼠小肠推进率无明显影响,薄荷醇用量加倍后,小鼠小肠推进率降低50%,与对照组比较有明显的差异。
5.3 改善皮肤组织结构、促进透皮吸收作用
薄荷醇可以促进扑热息痛、达克罗宁、水杨酸等多种药物的透皮吸收。以胎龄为7-8个月胎儿腹、背皮肤作透皮吸收实验模型,1%、2.5%、5%的薄荷脑均有显著促进扑热息痛透皮吸收作用,其机制与引起皮肤超微结构的改变有关。采用电刺激法测定用药前后豚鼠皮肤产生反应的阈电压,以阈电压升高率对时间作图,根据峰时、峰值和曲线下面积等指标考察达克宁表面麻醉作用,其机制是促进达克罗宁的透皮吸收。在整体兔,薄荷醇使水杨酸经皮吸收入血量明显增加,其Cmax和Auc1-12h分别提高151%和87.2%。用离体小鼠皮肤研究薄荷醇对水杨酸透皮吸收过程,结果水杨酸乙醇液加入1.5%薄荷醇可明显增加水杨酸的透皮累积量。薄荷醇可以促进四环素、利福平、林可霉素、灰黄霉素、甲硝唑、二氯苯咪唑的透皮吸收,且存在剂量效应关系。3.0%的薄荷醇的促皮渗透作用与2.0%月桂氯[艹卓]酮无明显差别。10%薄荷醇石蜡油15ml/kg灌胃,可明显延长磺胺嘧啶在大鼠体内分布相半衰期,增加磺胺嘧啶在大鼠脑内的浓度;0.5g/kg灌胃还可促进伊文思蓝透过小鼠血脑屏障。
Claims (7)
1.用于治疗忧郁症、消愁解忧、善解抑郁功效的中药薄荷,其特征是:由以下重量份的原料药组成:薄荷(新鲜根、茎、叶)1~1000份、郁金1~20份、木香1~15份、川楝子1~30、乌药1~20、降香1~20份、沉香1~15份、枳实1~30份、青皮1~20份。
2.按照权利要求1所述的中药组合物,其特征是:各原料药的重量份是:薄荷(新鲜根、茎、叶)1~50份、郁金15份、木香15份、川楝子15、乌药15、降香15份、沉香10份、枳实15份、青皮10份。
3.按照权利要求1所述的中药组合物,其中原料药还有:陈皮1~30份、神曲1~30份、酸枣仁1~15份、夜交藤1~15份、乌药1~30份、苏合香1~20份、石菖蒲1~30份、香附子1~30份。
4.按照权利要求3所述的中药组合物,其中各原料药的重量份是:陈皮20份、神曲20份、酸枣仁10份、夜交藤10份、乌药15份、苏合香15份、石菖蒲15份、香附子15份。
5.按照权利要求1、2、3或4所述的任意一项中药组合物,其特征是:按照常规的中药制剂方法制备成任何一种常用的口服制剂。
6.按照权利要求5所述的中药组合物,其特征是:所述的口服制剂是丸剂、胶囊剂、片剂、散剂、颗粒剂或口服液。
7.权利要求1~6任一项所述的中药组合物在制备用于治疗忧郁症、消愁解忧、善解抑郁功效的中药中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011102052844A CN102258751A (zh) | 2011-07-21 | 2011-07-21 | 用于治疗忧郁症、消愁解忧、善解抑郁的中药薄荷 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011102052844A CN102258751A (zh) | 2011-07-21 | 2011-07-21 | 用于治疗忧郁症、消愁解忧、善解抑郁的中药薄荷 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102258751A true CN102258751A (zh) | 2011-11-30 |
Family
ID=45005716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011102052844A Pending CN102258751A (zh) | 2011-07-21 | 2011-07-21 | 用于治疗忧郁症、消愁解忧、善解抑郁的中药薄荷 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102258751A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104207117A (zh) * | 2013-05-30 | 2014-12-17 | 吉林省现代中药工程研究中心有限公司 | 一种缓解焦虑的营养食品及制备方法 |
CN104327952A (zh) * | 2014-10-27 | 2015-02-04 | 山西大学 | 碰碰香精油及其提取方法和应用 |
CN105228600A (zh) * | 2013-05-24 | 2016-01-06 | 雀巢产品技术援助有限公司 | 使用薄荷醇、芳樟醇和/或冰素治疗或预防孤独症障碍的方法 |
CN105263481A (zh) * | 2013-05-24 | 2016-01-20 | 雀巢产品技术援助有限公司 | 使用薄荷醇和/或冰素治疗或预防抑郁 |
CN105581871A (zh) * | 2016-02-26 | 2016-05-18 | 仲景宛西制药股份有限公司 | 一种具有抑菌除臭作用的妇女卫生用药布 |
CN105747720A (zh) * | 2016-02-27 | 2016-07-13 | 宁波高新区苗姑养生科技有限公司 | 一种防治肝郁痰扰型心境恶劣障碍的理疗枕 |
CN115845014A (zh) * | 2022-12-21 | 2023-03-28 | 海南大学 | 一种治疗抑郁症的配方及其制备方法 |
-
2011
- 2011-07-21 CN CN2011102052844A patent/CN102258751A/zh active Pending
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105228600A (zh) * | 2013-05-24 | 2016-01-06 | 雀巢产品技术援助有限公司 | 使用薄荷醇、芳樟醇和/或冰素治疗或预防孤独症障碍的方法 |
CN105263481A (zh) * | 2013-05-24 | 2016-01-20 | 雀巢产品技术援助有限公司 | 使用薄荷醇和/或冰素治疗或预防抑郁 |
US20160108005A1 (en) * | 2013-05-24 | 2016-04-21 | Nestec S.A. | Treatment or prevention of depression using menthol and/or icilin |
US10369151B2 (en) | 2013-05-24 | 2019-08-06 | Societe Des Produits Nestle S.A. | Treatment or prevention of autism disorders using menthol, linalool and/or icilin |
CN105228600B (zh) * | 2013-05-24 | 2019-08-30 | 雀巢产品有限公司 | 使用薄荷醇、芳樟醇和/或冰素治疗或预防孤独症障碍的方法 |
US11241433B2 (en) | 2013-05-24 | 2022-02-08 | Societe Des Produits Nestle S.A. | Treatment or prevention of autism disorders using menthol, linalool and/or icilin |
CN104207117A (zh) * | 2013-05-30 | 2014-12-17 | 吉林省现代中药工程研究中心有限公司 | 一种缓解焦虑的营养食品及制备方法 |
CN104327952A (zh) * | 2014-10-27 | 2015-02-04 | 山西大学 | 碰碰香精油及其提取方法和应用 |
CN105581871A (zh) * | 2016-02-26 | 2016-05-18 | 仲景宛西制药股份有限公司 | 一种具有抑菌除臭作用的妇女卫生用药布 |
CN105747720A (zh) * | 2016-02-27 | 2016-07-13 | 宁波高新区苗姑养生科技有限公司 | 一种防治肝郁痰扰型心境恶劣障碍的理疗枕 |
CN115845014A (zh) * | 2022-12-21 | 2023-03-28 | 海南大学 | 一种治疗抑郁症的配方及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102258751A (zh) | 用于治疗忧郁症、消愁解忧、善解抑郁的中药薄荷 | |
CN111110898A (zh) | 一种具有香精的本草原露雾化液 | |
CN103169928B (zh) | 治疗痛经的外用中药组合物及其制备方法和应用 | |
CN101732558A (zh) | 一种用于治疗慢性咽炎的中药颗粒剂 | |
CN102178804B (zh) | 一种治疗肛周湿疹的中药组合物及其制备方法 | |
CN103893727A (zh) | 一种止痛活血舒筋贴膏及其制备方法 | |
CN105616590A (zh) | 一种具有清咽功能的组合物及其制备方法 | |
CN111150822A (zh) | 一种多功能本草原露雾化液 | |
CN103830636A (zh) | 一种治疗支气管炎哮喘的药物组合物 | |
CN103071134B (zh) | 治疗风湿关节疼痛和跌打肿痛的外用制剂及其制备方法 | |
CN101380406A (zh) | 一种用于治疗唇炎的药物及其制备方法 | |
CN104147538A (zh) | 一种治疗湿热毒盛型糖尿病足的中药制剂及其制备方法 | |
CN103599455B (zh) | 一种用于祛斑的中药胶囊 | |
CN104587319A (zh) | 一种修复剖腹产疤痕的药膏 | |
CN101066397A (zh) | 一种祛痤疮的保健品 | |
CN103638336B (zh) | 全天麻片 | |
CN112043773A (zh) | 一种调理体质和防治各型银屑病的智能系统制剂及制法 | |
CN101569714B (zh) | 治疗慢性咽炎的中药复方及其制备方法 | |
CN1840112A (zh) | 复方西羚解毒胶囊制剂及其制备方法 | |
CN104906345A (zh) | 用于治疗稳定期慢性阻塞性肺疾病的中药组合物 | |
CN104606636A (zh) | 一种治疗抑郁症的中药组合物及其制备方法 | |
CN110384785A (zh) | 一种用于治疗病毒性感冒的外用中药药液及其制备方法 | |
CN103920010A (zh) | 具有止血止痛及抗炎作用的药物组合物及其制备方法和用途 | |
CN1558767A (zh) | 一种治疗鼻塞、头痛的中药组合物及其制备方法 | |
CN105012483A (zh) | 一种治疗头部脂溢性皮炎的中药组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111130 |